Skip to main content
. 2021 Nov 30;9(12):1413. doi: 10.3390/vaccines9121413

Table 4.

Efficacy and effectiveness of HPV vaccination against human papillomavirus in males.

Outcome Type of Vaccine Dose of Vaccine HPV Status at Enrolment Vaccine Efficacy or Effectiveness
(95% CI)
Seroconversion after 1 month
to HPV 6/11/16/18 [63]		 Quadrivalent vaccine Three doses Irrespective 97.4%
DNA detection of HPV (intention-to-treat population) [63,64] Quadrivalent vaccine At least one dose

  • HPV 6

 Irrespective 35.1% (20.3% to 47.3%) to 61.5% (42.3% to 74.8%)
Naive 46.5% (30.2% to 59.2%)

  • HPV 11

 Irrespective 43.2% (18.7% to 60.7%) to 54.7% (22.6% to 74.3%)
Naive 50.5% (20.1% to 70.0%)

  • HPV 16

 Irrespective 28.0 (12.9 to40.7) to 45.1% (18.0% to 63.7%)
Naive 29.4% (10.1% to 44.7%)

  • HPV 18

 Irrespective 33.9% (13.0% to 50.1%) to 49.5% (11.3% to 72.1%)
Naive 45.0% (23.7% to 60.7%)
Persistent infection (intention-to-treat population) [63,64] Quadrivalent vaccine At least one dose

  • HPV 6

 Irrespective 44.7% (24.1 to 60.1) to 62.5%(37.5 to 78.2)

  • HPV 11

 Irrespective 53.7% (7.5 to 78.0) to 59.4%(25.7 to 78.8)

  • HPV 16

 Irrespective 46.9% (28.6 to 60.8) to 54.0%(23.9 to 72.9)

  • HPV 18

 Irrespective 56.0% (28.2 to 73.7) to 73.6%(37.5 to 90.3)
Condyloma acuminate [63,64] Quadrivalent vaccine At least one dose Irrespective 57.2(15.9 to79.5) to 67.2% (47.3% to 80.3%)
PIN grade 1 [63] Quadrivalent vaccine At least one dose Irrespective 25.6% (−339.9 to 89.1)
PIN grade 2 or 3 [63] Quadrivalent vaccine At least one dose Irrespective −48.9% (−1682.6 to 82.9)
AIN grade 1 [64] Quadrivalent vaccine At least one dose Irrespective 49.6% (21.2% to 68.4%)
AIN grade 2 Quadrivalent vaccine At least one dose Irrespective 61.9% (21.4% to 82.8%)
AIN grade 3 Quadrivalent vaccine At least one dose Irrespective 46.8% (−20.2% to 77.9%)